PRO-122

DRUG3 trials

Sponsors

Laboratorios Sophia S.A de C.V.

Conditions

GlaucomaOcular HypertensionPrimary Open Angle GlaucomaPrimary Open-angle Glaucoma

Phase 1

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®

CompletedNCT03966365

Laboratorios Sophia S.A de C.V.Glaucoma

Start: 2019-05-02End: 2019-08-30Updated: 2019-12-13

Phase 3

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

TerminatedNCT03193333

Laboratorios Sophia S.A de C.V.Primary Open-angle Glaucoma

Start: 2017-11-06End: 2024-10-30Updated: 2025-03-06

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

CompletedNCT03257813

Laboratorios Sophia S.A de C.V.Ocular Hypertension, Primary Open Angle Glaucoma

Start: 2016-04-01End: 2017-06-18Updated: 2019-12-09

Related Papers

Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials

Therapeutics and Clinical Risk Management2021-10-013 citations

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma

Ophthalmology and Therapy2018-04-2112 citations